EFCLAROFUSP ALFA
UNII 3E9XUG7SWS

Substance Identification & Data

This profile provides standardized clinical and technical data for Efclarofusp Alfa, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 3E9XUG7SWS.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3053638-35-7 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

3E9XUG7SWS

CAS Registry Number

3053638-35-7

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

EFCLAROFUSP ALFA

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C216019

National Cancer Institute reference terminology for clinical and research data.

INN ID

13543

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

Efclarofusp alfa

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Efclarofusp Alfa. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

Common Names & Synonyms

Efclarofusp alfa

Vascular endothelial growth factor receptor 1 (human extracellular immunoglobulin domain 2 fragment) fusion protein with vascular endothelial growth factor receptor 2 (human extracellular immunoglobulin domain 3 fragment) fusion protein with immunoglobulin G1 (human γ-1 chain hinge-CH2-CH3 fragment) fusion protein with synthetic linker ((GGGGS)3) fusion protein with rhodostomin [39-lysine,40-lysine,42-arginine,43-threonine,46-alanine,47-arginine,48-glycine,51-aspartic acid,52-asparagine] (Calloselasma rhodostoma), dimer

efclarofusp alfa [INN]

human vascular endothelial growth factor receptor 1 (VEGFR1, vascular permeability factor receptor, Fms-like tyrosine kinase 1, FLT1, tyrosine-protein kinase receptor FLT, tyrosine-protein kinase FRT, EC:2.7.10.1), fragment 103-206 (containing the Ig-like C2-type domain 2) (1-104), fused to human vascular endothelial growth factor receptor 2 (VEGFR2, fetal liver kinase 1, FLK1, protein-tyrosine kinase receptor flk-1, kinase insert domain receptor, KDR, CD309, EC:2.7.10.1), fragment 208-308 (containing the Iglike C2-type domain 3) (105-205), fused to an immunoglobulin G1 (IgG1) Fc fragment (h-CH2-CH3-CHS domains) (206-431) [Homo sapiens IGHG1*01 (hinge (206-215), CH2 (216-325), CH3 (326-430), CHS K432>del (431-431))] fused via the peptide linker (G4S)3 (432-446) to disintegrin rhodostomin [Calloselasma rhodostoma (Malayan pit viper, Agkistrodon rhodostoma)] (447-514), [S39<su/p>>K485, R40>K486, G42>R488, K43>T489, R46>A492, I47>R493, P48>G494, M52>N498]-variant; dimer (211-211':214-214')-bisdisulfide; produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1; glycoform alfa

External Clinical & Regulatory Resources

Previous UNII3E9T80FR85

Next UNII3EAX4274NS